? OVERALL This is a renewal application for support of the Yale University Digestive Disease Research Core Center, a multidisciplinary Center whose research focus is Liver Structure, Function and Disease. Thirty-four independently funded investigators comprise a current digestive disease related-research base of ~$23 million, and all of these individuals actively collaborate with other Liver Center members. There are an additional 52 associate members engaged in liver-related research, 40% of whom also have independent funding. Research programs in the Center are distributed across 17 Departments of the University including Biomedical Engineering; Cell Biology; Cellular and Molecular Physiology; Comparative Medicine; Epidemiology and Public Health; Human Genetics; Immunobiology; Internal Medicine; Microbial Pathogenesis; Molecular Biophysics and Biochemistry; Obstetrics and Gynecology; Pathology; Pediatrics; Pharmacology; Radiology, Surgery, and Urology. The research base focuses on three major basic/translational themes: (1) Hepatic metabolism, (2) Immunobiology and inflammation, and (3) Epithelial biology/pathobiology. The research programs are broad and range from fundamental studies of the biology of liver and related digestive systems to translational studies of immediate clinical relevance. The major areas of liver disease examined within these translational themes include autoimmune diseases, cholestasis, fibrosis/cirrhosis, genetic diseases, infections, liver cancer, and NASH/ASH. The major goals of the Center continue to be: (1) to stimulate multidisciplinary interactions between basic and clinical faculty and departments, (2) to provide an in-depth training environment, (3) to efficiently organize time consuming, often costly techniques and procedures in Core Facilities for use by multiple investigators, (4) to stimulate basic scientists to direct their focus to areas of interest to the Center, (5) to stimulate translational research from bench to bedside, (6) to promote new research and training opportunities with a pilot feasibility program, and (7) to create an intellectual environment within the field by fostering collaborations both within and outside the institution through its enrichment program. To achieve these goals the Center is organized into four Core Facilities including: (1) Administrative Core, (2) Cellular and Molecular Physiology Core, (3) Morphology Core and (4) Clinical/Translational Core. A Pilot Feasibility Program supports one- to two-year small grants for new scientific initiatives. The Enrichment Program consists of research seminars, symposia, visiting professorships, and retreats.
? OVERALL Liver disease affects nearly one in three Americans. The Yale Liver Center's mission is to enhance knowledge of the etiology, diagnosis and treatment of liver diseases and other related disorders of the digestive system, thereby advancing the nation's public health. It does so by simulating both basic, translational and clinical research in this discipline at the University and by establishing core research facilities for use by multiple liver investigators.
|Franca, Andressa; Filho, Antonio Carlos Melo Lima; Guerra, Mateus T et al. (2018) Effects of endotoxin on type 3 inositol 1,4,5-trisphosphate receptor in human cholangiocytes. Hepatology :|
|Liu, Chune; Yang, Zhihong; Wu, Jianguo et al. (2018) Long noncoding RNA H19 interacts with polypyrimidine tract-binding protein 1 to reprogram hepatic lipid homeostasis. Hepatology 67:1768-1783|
|Brivio, Simone; Cadamuro, Massimiliano; Fabris, Luca et al. (2018) Molecular Mechanisms Driving Cholangiocarcinoma Invasiveness: An Overview. Gene Expr 18:31-50|
|Cox, Carly S; McKay, Sharen E; Holmbeck, Marissa A et al. (2018) Mitohormesis in Mice via Sustained Basal Activation of Mitochondrial and Antioxidant Signaling. Cell Metab 28:776-786.e5|
|Madiraju, Anila K; Qiu, Yang; Perry, Rachel J et al. (2018) Metformin inhibits gluconeogenesis via a redox-dependent mechanism in vivo. Nat Med 24:1384-1394|
|Schmitz, Corinna; Noels, Heidi; El Bounkari, Omar et al. (2018) Mif-deficiency favors an atheroprotective autoantibody phenotype in atherosclerosis. FASEB J 32:4428-4443|
|Pan, Qiong; Zhang, Xiaoxun; Zhang, Liangjun et al. (2018) Solute Carrier Organic Anion Transporter Family Member 3A1 Is a Bile Acid Efflux Transporter in Cholestasis. Gastroenterology 155:1578-1592.e16|
|Jakab, Sofia Simona; Garcia-Tsao, Guadalupe (2018) Screening and Surveillance of Varices in Patients With Cirrhosis. Clin Gastroenterol Hepatol :|
|Fiorotto, Romina; Amenduni, Mariangela; Mariotti, Valeria et al. (2018) Src kinase inhibition reduces inflammatory and cytoskeletal changes in ?F508 human cholangiocytes and improves cystic fibrosis transmembrane conductance regulator correctors efficacy. Hepatology 67:972-988|
|Sari, Sinan; Dalgic, Buket; Muehlenbachs, Atis et al. (2018) Prototheca zopfii Colitis in Inherited CARD9 Deficiency. J Infect Dis 218:485-489|
Showing the most recent 10 out of 763 publications